Finance entity
Every one of those 2 sits in a single category, regulation. Of the tracked stories, 2 of 2 also mention FDA, the most common co-covered peer. The 7.5 average consequence score is above the beat benchmark of 6.7 in the same window.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, regulation. Of the tracked stories, 2 of 2 also mention FDA, the most common co-covered peer. The 7.5 average consequence score is above the beat benchmark of 6.7 in the same window. Source depth averages 4.5 original sources per story, versus 4.7 across the same-window beat baseline. mRNA-1010 appears in 2 tracked Finance stories from February 18, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 90 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering mRNA-1010. Shared-story counts are live from our verified record — not editorial picks.
FDA U-Turn
Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
Public Dispute
Moderna and administration officials engage in a public disagreement over the regulatory path forward.
Initial Rejection
Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.
The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
Source: news8000.com · wlfi.com
The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
mRNA-1010 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
